CAM 2028

Drug Profile

CAM 2028

Alternative Names: Benzydamine CR; CAM2028; Episil; episil; episil® oral liquid; SP-03 - Camurus

Latest Information Update: 09 Mar 2017

Price : $50

At a glance

  • Originator Camurus
  • Developer Camurus; Solasia Pharma; Takeda Pharmaceuticals International GmbH
  • Class Analgesics
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Stomatitis

Most Recent Events

  • 09 Mar 2017 CAM 2028 licensed to Ethypharm in France
  • 16 Feb 2017 CAM 2028 licensed to Lees Pharmaceutical in China, Hong Kong and Macau
  • 05 Dec 2016 CAM 2028 licensed to Meiji Seika Pharma in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top